The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients

Objective.  To determine the contribution of classical risk factors to the development of cardiovascular disease (CVD) in patients with heterozygous familial hypercholesterolaemia (FH).

[1]  J. Ferrières,et al.  Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. , 1995, Circulation.

[2]  M. Schemper,et al.  Predictive Accuracy and Explained Variation in Cox Regression , 2000, Biometrics.

[3]  E. Boerwinkle,et al.  Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. , 1990, The New England journal of medicine.

[4]  R. Westendorp,et al.  Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. , 2000, Atherosclerosis.

[5]  Nicholas Smith,et al.  Smoking Status and Risk for Recurrent Coronary Events after Myocardial Infarction , 2002, Annals of Internal Medicine.

[6]  W. Riley,et al.  Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. , 2001, The American journal of cardiology.

[7]  A. Zwinderman,et al.  Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.

[8]  S. Kihara,et al.  Characteristics of coronary artery disease and lipoprotein abnormalities in patients with heterozygous familial hypercholesterolemia associated with diabetes mellitus or impaired glucose tolerance. , 1997, Atherosclerosis.

[9]  H. Hobbs,et al.  Lipoprotein(a): intrigues and insights. , 1999, Current opinion in lipidology.

[10]  F. Kronenberg,et al.  Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[11]  M. Hayden,et al.  Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[12]  J. Danesh,et al.  Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.

[13]  J. Kastelein,et al.  The molecular basis of familial hypercholesterolemia in The Netherlands , 2001, Human Genetics.

[14]  J. Kastelein,et al.  Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia , 2003, Journal of internal medicine.

[15]  J. Beaumont,et al.  Ischaemic disease in men and women with familial hypercholesterolaemia and xanthomatosis. A comparative study of genetic and environmental factors in 274 heterozygous cases. , 1976, Atherosclerosis.

[16]  J J Kastelein,et al.  Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. , 2001, BMJ : British Medical Journal.

[17]  B. Angelin,et al.  Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia , 1990, The Lancet.

[18]  Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. , 1991, BMJ.

[19]  G. Boers,et al.  Carotid and femoral artery wall thickness and stiffness in patients at risk for cardiovascular disease, with special emphasis on hyperhomocysteinemia. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[20]  T. Miettinen,et al.  Mortality and cholesterol metabolism in familial hypercholesterolemia. Long-term follow-up of 96 patients. , 1988, Arteriosclerosis.

[21]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[22]  Plasma Homocysteine as a Risk Factor for Vascular Disease , 1998 .

[23]  T. Farag,et al.  Familial hypercholesterolemia. , 1988, Journal of the Royal Society of Medicine.

[24]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[25]  D B Rubin,et al.  Multiple imputation in health-care databases: an overview and some applications. , 1991, Statistics in medicine.

[26]  E. Boerwinkle,et al.  Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. , 1992, The Journal of clinical investigation.

[27]  Per Magne Ueland,et al.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. , 2002, JAMA.

[28]  J. Witteman,et al.  Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. , 1997, JAMA.